Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

Non-Small Cell Lung Cancer Collaborative Group, 1995, Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899 2004, American Society of Clinical Oncology. Treatment of unresectable non-small-cell-lung cancer guideline: update 2003, J Clin Oncol, 22, 330, 10.1200/JCO.2004.09.053 Huisman, 2000, Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review, J Clin Oncol, 18, 3722, 10.1200/JCO.2000.18.21.3722 Fossella, 1994, Phase II study of docetaxel for advanced or metastatic platinum refractory non-small-cell lung cancer, J Clin Oncol, 12, 1238, 10.1200/JCO.1994.12.6.1238 Gandara, 2000, Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial, J Clin Oncol, 18, 131, 10.1200/JCO.2000.18.1.131 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 Altstadt, 2001, Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476, J Med Chem, 44, 4577, 10.1021/jm0102607 Giannakakou, 2000, A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells, Proc Natl Acad Sci USA, 97, 2904, 10.1073/pnas.040546297 Rose, 2001, Preclinical antitumor activity of two novel taxanes, Cancer Chemother Pharmacol, 47, 97, 10.1007/s002800000241 Hidalgo, 2001, Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J Clin Oncol, 19, 2493, 10.1200/JCO.2001.19.9.2493 Plummer, 2002, Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies, Clin Cancer Res, 8, 2788 Crino, 1999, Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial, J Clin Oncol, 17, 2081, 10.1200/JCO.1999.17.7.2081 Belani, 1998, Single agents in the second-line treatment of non-small cell lung cancer, Semin Oncol, 25, S10 Kruijtzer, 2002, Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer, J Clin Oncol, 20, 4508, 10.1200/JCO.2002.04.058 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Sun, 2003, Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered a 1-hour intravenous infusion in combination with cisplatin every 21 days, Clin Cancer Res, 9, 5221 Bilenker, 2004, Phase I trial of the novel taxane BMS-184476 admnistered in combination with carboplatin every 21 days, Br J Cancer, 91, 213, 10.1038/sj.bjc.6601885